Viridian Therapeutics, Inc.\DE
VRDNNasdaq
$18.03
0.0%Jul 17 close · end-of-day
Price
1Y↑ +7.4%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$70.9M
Net Income (TTM)
-$360.6M
Free Cash Flow (TTM)
-$303.8M
Gross Margin
—
Operating Margin
-543.9%
Net Margin
-508.5%
ROE
-56.7%
ROIC
-607.3%
Debt / Equity
—
Net Cash
$585.8M
Return 1Y
+5.8%
Company profile
Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
- CEO
- Jonathan Violin
- Sector
- Services
- Industry
- Healthcare
- Employees
- 50
- Headquarters
- Massachusetts
- Website
- viridiantherapeutics.com
Earnings
VRDN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$141,000.00↑ +95.8%
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1M | $3.0M | $1.8M | $314,000.00 | $302,000.00 | $70.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$110.4M | -$79.7M | -$134.3M | -$254.4M | -$299.0M | -$363.4M |
| Net income | -$110.7M | -$79.4M | -$129.9M | -$237.7M | -$269.9M | -$342.6M |
| Diluted EPS | -$31.13 | -$6.66 | -$4.05 | -$5.31 | — | — |
| Operating cash flow | -$29.8M | -$54.6M | -$93.8M | -$184.2M | -$232.3M | -$276.4M |
| Free cash flow | -$29.8M | -$54.9M | -$94.6M | -$185.1M | -$232.8M | -$276.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -10512.4% | -2690.8% | -7579.2% | -81035.0% | -99018.2% | -512.9% |
| Net margin | -10544.3% | -2679.7% | -7330.7% | -75700.6% | -89370.9% | -483.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $72,000.00 | $86,000.00 | $72,000.00 | $72,000.00 | $75,000.00 | $70.6M | $132,000.00 | $141,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$72.2M | -$83.5M | -$87.5M | -$93.9M | -$106.8M | -$40.0M | -$122.7M | -$116.2M |
| Net income | -$65.0M | -$76.7M | -$79.7M | -$86.9M | -$100.7M | -$34.6M | -$120.4M | -$104.9M |
| Diluted EPS | -$1.02 | -$1.15 | — | — | — | — | — | — |
| Operating cash flow | -$46.1M | -$67.7M | -$73.3M | -$92.7M | -$75.4M | -$84.6M | -$23.8M | -$119.7M |
| Free cash flow | -$46.2M | -$68.0M | -$73.4M | -$92.7M | -$75.4M | -$84.7M | -$24.0M | -$119.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -100259.7% | -97069.8% | -121487.5% | -130369.4% | -142356.0% | -56.7% | -92991.7% | -82389.4% |
| Net margin | -90268.1% | -89173.3% | -110661.1% | -120711.1% | -134313.3% | -49.0% | -91177.3% | -74397.9% |
Company news
Jul 15, 2026
Jul 14, 2026
Jul 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.